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Abstract: OBJECTIVES: We aimed to evaluate and quantify incompatible coadministrations of contin-
uous intravenous medication in the daily clinical practice of a PICU/NICU. METHODS: We conducted
a retrospective, observational study in the setting of an 18-bed PICU/NICU. All concurrently admin-
istered continuous infusions, including blood products and parenteral nutrition, were analyzed for 2
months. Raw electronic data were retrieved and subjected to quality controls. Infusion combinations
were classified as compatible, incompatible, no data, or variable according to the internal hospital charts,
Trissel’s database, and the Swiss summary of product characteristics. For situations with incompatible
coadministrations, we assessed alternative distributions of infusions among the currently available lumen.
RESULTS: Data for 100 patients were analyzed. Patients were exposed to a mean of 6.9 ± 3.6 individual
continuous infusions administered through 3.8 ± 1.8 lumina. Among the 1447 coadministered continuous
infusions, we detected 146 incompatible combinations (10%), resulting in 105 individually relevant in-
compatible situations. Furthermore, 185 combinations (13%) were not covered by internal compatibility
charts, and for 207 combinations (15%) no data on compatibility were available. We found that 58% of
the incompatible situations could have been avoided by a redistribution of the infusions among the avail-
able lumina. CONCLUSIONS: Most infusion combinations in the studied PICU/NICU were compatible
and covered by the internal compatibility charts. However, we also identified concurrent administrations
of incompatible infusions or for which compatibility data are not available. A significant reduction of
coadministrations of incompatible infusions could be achieved through optimal use of available lumina.
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OBJECTIVES We aimed to evaluate and quantify incompatible coadministrations of continuous intravenous 
medication in the daily clinical practice of a PICU/NICU.
METHODS We conducted a retrospective, observational study in the setting of an 18-bed PICU/NICU. All 
concurrently administered continuous infusions, including blood products and parenteral nutrition, were 
analyzed for 2 months. Raw electronic data were retrieved and subjected to quality controls. Infusion 
combinations were classified as compatible, incompatible, no data, or variable according to the internal 
hospital charts, Trissel’s database, and the Swiss summary of product characteristics. For situations with 
incompatible coadministrations, we assessed alternative distributions of infusions among the currently 
available lumen.
RESULTS Data for 100 patients were analyzed. Patients were exposed to a mean of 6.9 ± 3.6 individual 
continuous infusions administered through 3.8 ± 1.8 lumina. Among the 1447 coadministered continuous 
infusions, we detected 146 incompatible combinations (10%), resulting in 105 individually relevant 
incompatible situations. Furthermore, 185 combinations (13%) were not covered by internal compatibility 
charts, and for 207 combinations (15%) no data on compatibility were available. We found that 58% of the 
incompatible situations could have been avoided by a redistribution of the infusions among the available 
lumina.
CONCLUSIONS Most infusion combinations in the studied PICU/NICU were compatible and covered by 
the internal compatibility charts. However, we also identified concurrent administrations of incompatible 
infusions or for which compatibility data are not available. A significant reduction of coadministrations of 
incompatible infusions could be achieved through optimal use of available lumina.
ABBREVIATIONS MNIC, maximum number of infusion combinations; NICU, neonatal intensive care unit; 
PICU, pediatric intensive care unit; PIM, pediatric index of mortality; PN, parenteral nutrition; SPC, summary 
of product characteristics
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Introduction
Intravenous medication administration is a complex 
procedure involving several steps and is therefore 
prone to errors.1,2 Moreover, critically ill children fre-
quently need numerous drugs and other delicate infu-
sions, including blood products or parenteral nutrition 
(PN), to be applied via a limited number of available 
lumina. However, to the best of our knowledge, no 
study has assessed the compatibility of coadministered 
continuous infusion considering PN and blood products 
in the setting of a PICU/NICU in daily clinical practice.
Incompatible coadministration of IV drugs may 
result in complications ranging from simple catheter 
obstruction to fatality.3,4 Incompatibilities are caused by 
physical (precipitation, color change, gas production) 
or chemical (oxidation, reduction, hydrolysis, decom-
position) reactions, usually occurring outside the body 
between 2 products.5 Also, infants and children are at 
an increased risk for developing particulates because of 
the small size of their veins,6 causing endothelial dam-
age and inflammation leading to phlebitis or pulmonary 
embolism.6,7 Although several cases of severe clinical 
outcomes due to incompatibility issues have been 
reported,3,8–10 a recent French review of the literature 
covering adult and pediatric settings found that only 
limited data are available on this topic.4 A previous 
Swiss study observed incompatibilities in 3.4% of the 
administered IV medication on a PICU,11 and a recent 
Canadian analysis concluded that 9% of the concurrent 
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infusion administrations were incompatible.12 Previous 
studies found that 10% to 50% of the drug combinations 
reported in previous studies were administered without 
compatibility data.11,13,14 This lack of data on compatibility 
further compromises the patient’s safety. In addition, 
the compatibility of PN and blood products remains 
largely unexplored and/or ambiguous and is therefore 
generally not recommended.15,16
Literature and our clinical experience suggest that 
patients on our PICU/NICU are occasionally exposed 
to incompatible coadministrations. Therefore, the aim 
of the present study was to assess the frequency and 
nature of incompatible coadministration of continuous 
infusions on our PICU/NICU. Furthermore, we presumed 
that incompatible coadministrations may be avoided 
if nurses and physicians are adhering to compatibility 
charts, provided they cover combinations occurring in 
clinical practice.
Because incompatibilities are administration errors, 
which have been demonstrated to be preventable by 
compatibility tools and/or the assistance of pharmaceu-
tical services, the present study may contribute to the 
development and implementation of specific actions 
that increase patients’ safety.14,17,18
Methods
We conducted an observational, retrospective study 
in the PICU/NICU of the University Children’s Hospital in 
Zurich. It features 18 beds and is dedicated to patients 
ranging from preterm babies to adolescents up to 16 
years. All patients admitted to the PICU/NICU from 
February 4 to April 4, 2018, were included, with the 
exception of patients for whom the parents refused 
consent to use personal medical data for research 
purposes. Patients who did not concurrently receive at 
least 2 continuous infusions in the same lumen were 
also excluded, as depicted in Figure 1. Approval from 
the Swiss Ethics Committee was obtained before the 
start of the study.
Data was compiled daily in intervals from 2:00 p.m. 
to 1:59 p.m. based on electronic patient documentation. 
The primary source for all data in this study originated 
from the 2 clinical information systems used for pa-
tients hospitalized on the PICU/NICU. These software 
programs were Phoenix (version 7.14.0.5, CompuGroup, 
Bern, Switzerland), a clinical information system and 
MetaVision (version 5.46, iMDSoft, Tel Aviv, Israel), an 
intensive care unit patient-data management system.
A quality assessment to identify whether the elec-
tronic patient records corresponded to the actual 
distribution of the infusions among the available lumina 
was performed: As a quality control, the documenta-
tion of infusions in the clinical information systems was 
printed out and compared to the actual configuration 
of infusions and lumina at the bedside of the patients 
upon 8 unannounced occasions during different day-
times and weekdays.
Each combination of continuous infusions was con-
sidered (i.e., drugs, electrolyte solutions, PN, and blood 
products). Data on IV injections and infusions lasting 
less than 15 minutes were not considered because 
they were not sufficiently documented in the electronic 
medical records. The following patient parameters were 
anonymously recorded: sex, age, weight, length of stay, 
pediatric index of mortality (PIM) upon admission on 
the PICU/NICU, number of central venous catheters, 
the number of available IV lumina and all administered 
continuous infusions.
An infusion combination was defined as any combi-
nation of at least 2 infusions concurrently administered 
into the same lumen. Whenever 1 infusion was added 
(or removed if 2 or more infusions were combined) to 
any combination it was assessed as an additional com-
bination. We then combined multiple related incompat-
ible combinations into single incompatible situations, 
which are more representative of clinical practice: they 
represent potentially dangerous coadministrations of 
infusions that need to be addressed coincidentally. The 
compatibility checks for infusion combinations were 
Figure 1. Flowchart of patients included during the 
study period of February 4 to April 4, 2018.
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made pairwise using 3 different references. Primarily, 
combinations were verified using internal compatibility 
charts developed by the pharmaceutical services of the 
University Children’s Hospital Zurich. These charts were 
compiled by interpreting several compatibility refer-
ences (Trissel’s database; manufacturer information, 
such as pH values; Swiss summary of product charac-
teristics [SPC]). For commonly occurring combinations 
on which the Swiss SPC, Trissel’s, or primary literature 
did not provide any data, the following principles 
were applied to develop the charts: combinations of 
IV medications were considered incompatible if their 
pH differed by a value of more than 2 or if any of the 
involved medications contained critical excipients, 
such as buffers or solubilizers. Any blood products or 
proteins were also generally considered incompatible 
with any other IV medication unless there was specific 
compatibility data available.
If infusion combinations did not feature on the in-
ternal compatibility charts, compatibility data in the 
Trissel’s database (website of Micromedex) and the 
Swiss SPC were consulted for classification. Infusion 
combinations were classified in 4 categories: compat-
ible, incompatible, no data, or variable (concentration-
dependent). Likewise, all incompatible combinations 
classified as such based on the internal compatibility 
charts were rechecked in Trissel’s database and the 
Swiss SPC. This recheck served to assess whether the 
incompatibility on the internal compatibility charts was 
also described elsewhere or if it was a recommenda-
tion based on the evaluation of the pharmaceutical 
services. Because compatibility databases provide 
only information for infusion pairs, the compatibility 
of a combination composed of more than 2 infusions 
was derived to be compatible if all infusion pairs were 
compatible. In cases with more than 2 concurrent 
infusions, for which there were different compatibility 
categories, the compatibility of any such combination 
was assessed as a combination in the highest risk-tier. 
All incompatible situations of this study were reviewed 
for a compatible alternative redistributing the infusions 
among the available lumina.
We developed a score to represent the maximum 
number of infusion combinations (MNIC) patients were 
exposed to during their stay. Associations of this MNIC 
score and further patient parameters (age, PIM, length 
of stay on PICU/NICU) with occurrence of an incompat-
ible situation were analyzed with a logistic regression 
model in STATA (version 13.1, StataCorp, College Sta-
tion, TX). For each parameter, patients were divided 
in quartiles. The quartiles with the largest number of 
patients were used as reference groups. Statistical 
significance was defined by p < 0.05, and relative risks 
were calculated with their 95% CIs.
Results
A total of 100 patients were included in this study 
contributing overall 503 patient-days for further analy-
sis. Median age was 0.9 years, and 58% of the patients 
were male. Mean length of stay was 6.3 days and mean 
PIM for the included patients was 5.9%. Patients’ char-
acteristics are summarized in Table 1.
Our quality assessment of the documentation in the 
electronic medical records allowed the assessment 
of a total of 172 administrations among 44 individual 
patients. We identified 10 administrations of continu-
ous infusions that were not correctly documented in 
the electronic patient record patient data manage-
ment system, which corresponds to an error rate of 
5.8% (3.0% to 10.7% using a 95% CI). Detailed data are 
displayed in Table 2.
Overall, we compiled data on 3949 individual infu-
sions from which 1447 combinations of continuous infu-
sions were considered for this study. On average, pa-
tients had 2.7 catheters and received a mean 6.9 ± 3.6 
continuous infusions (range, 2–17) distributed among 
4 lumina (range, 1–8) per day. The most frequently ad-
ministered infusions were morphine (n = 437), followed 
by midazolam (n = 363) and saline solution 0.9% (n = 
251). The most frequent combination of concurrently 
administered infusions through the same lumen was 
midazolam and morphine (n = 232). Detailed results 
are presented in Table 3 and Supplemental Table 1.
Among the recorded combinations, 1077 were com-
posed of 2 concurrent infusions, and 370 combinations 
Table 1. Patient Characteristics
Parameter Value
Patients included, n 100
Patient-days included, no. (%) 503 (50)
Mean no. of patients included per day 8.4
Male sex, n (%) 58 (58)
Age at admission, yr
 Mean ± SD 2.6 ± 3.9
 Median (IQR) 0.9 (0.1–3.0)
 Range 0.003–13
Age distribution of patients, n (%)
 0–3 yr 78 (78)
 3.1–16 yr 22 (22)
Length of stay, days
 Mean ± SD 6.3 ± 8.2
 Median (IQR) 3.0 (2.0–8.0)
 Range 1–60
PIM at admission, %
 Mean ± SD 5.9 ± 11.4
 Median (IQR) 2.5 (1.1–5.4)
 Range 0.13–77.60
PIM, pediatric index of mortality
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(35%) consisted of 3 or more. A maximum number of 7 
continuous infusions were concurrently administered in 
the same lumen. Using the internal compatibility charts, 
146 combinations (10%) were classified as incompatible 
and 1061 (73%) as compatible. The compatibility of 185 
combinations (13%) was not available on the internal 
compatibility charts and was therefore categorized us-
ing the database of Trissel’s or the Swiss SPC. For 207 
infusion combinations (15%) that were coadministered, 
no data about their compatibility were available in any 
reference (Table 4). For 15 combinations of infusions 
(1%), data on compatibility were conflicting (Supple-
mental Table 2). These ambiguous combinations were 
discussed between three members of the pharmaceuti-
cal services until they agreed on a classification to the 
best of their pharmaceutical knowledge.
A total of 146 incompatible infusion combinations 
(10%) classified in 105 incompatible situations were 
recorded during 60 days, and 46 patients (46%) were 
exposed to at least 1 incompatible situation. The internal 
compatibility charts covered all incompatible combina-
tions. Among the 146 incompatible combinations, 11 
(8%) were also classified as incompatible in the Trissel’s 
database and/or in the Swiss SPC. For the 135 other 
combinations classified as incompatible in the internal 
compatibility charts there were no data available in 
Trissel’s and/or the Swiss SPC. Among the incompat-
ible combinations, the most frequently concerned 
infusions were blood products, which were present in 
34%. Midazolam, morphine, and tranexamic acid were 
also frequently involved in incompatibilities. Tranexamic 
acid with midazolam was the incompatible combination 
that occurred most frequently. Among the combina-
tions administered without data on compatibility, the 
most frequent combination was morphine with a mixed 
solution containing glucose (9.1%) and sodium chloride 
(0.9%). A summary of the results is listed in Table 5.
On average, patients exposed to an incompatible 
situation received 10 infusions distributed among 5 
lumina. The size of the dots in the bubble charts (Figure 
2) is proportional to the prevalence of incompatible 
situations. The distribution of the points demonstrates 
a proportional tendencyof incompatible situations (n 
= 105) according to the number of infusions and the 
number of lumina. The orange point represents the 
mean number of infusions and lumens had by the 
patient, when he or she was exposed to an incompat-
ible situation.
After considering the available lumina and all admin-
istered continuous infusions in the 105 incompatible 
situations, we assessed that for 61 (58%) there may 
have been an alternative distribution of the infusions 
by which the incompatible situation could have been 
avoided.
Results from the logistic regression are presented in 
Table 6. Associations between patient parameters and 
exposure to an incompatibility were strongest for the 
MNIC score. Although no significant association was 
found for age and PIM, patients who stayed longest 
were also more frequently exposed to incompatible 
situations.
Discussion
Our study confirmed that patients hospitalized on our 
PICU/NICU are exposed to incompatibilities. Although 
most infusion combinations were compatible, on aver-
age at least 1 incompatible situation (n = 105) occurred 
daily. We found that a limited number of infusions ac-
counted for most of the incompatible situations, many 
of which could have been theoretically avoided by 
redistributing the involved infusions among the avail-
able lumens. The results from the logistic regression 
suggest that the major risk factor for exposure to an 
incompatible situation is the patient’s number of infu-
sion combinations. Young age and PIM likely represent 
Table 2. Quality of Documentation: Data of Samples
Sample Date Time No. of Patients Patients Included 
(With Consent) 
No. of Infusions 
Controlled*
No. of Infusions 
Incorrectly 
Documented†
1 March 7, 2018 9:00 a.m. 6 4 26 4
2 March 8, 2018 9:00 a.m. 6 5 28 1
3 March 11, 2018 9:00 a.m. 6 4 24 0
4 March 11, 2018 12:00 p.m. 6 5 13 0
5 March 13, 2018 9:00 a.m. 7 4 21 1
6 March 13, 2018 9:00 a.m. 9 8 18 1
7 March 19, 2018 4:00 p.m. 8 7 18 1
8 March 20, 2018 10:00 a.m. 8 7 24 2
Total 56 44 172 10
* Comparing electronic documentation in pediatric database management system with actual distribution at bedside.
† Electronic documentation in pediatric database management system not corresponding to actual distribution at bedside.
Incompatible Continuous Infusions in a PICU/NICU Häni, C et al
 J Pediatr Pharmacol Ther 2019 Vol. 24 No. 6 483www.jppt.org 
Table 3. Administration of Continuous Infusions
Parameter Value
No. of catheters per patient per day
 Mean (SD) 2.7 (1.2)
 Median (IQR) 3.0 (2.0–4.0)
 Range 1–6
CVCs per patient per day
 Mean (SD) 0.8 (0.6)
 Median (IQR) 1.0 (1.0–1.0)
 Range 0–3
Lumina per patient per day
 Mean (SD) 3.8 (1.8)
 Median (IQR) 4.0 (2.0–5.0)
 Range 1–8
Infusions per patient per day
 Mean (SD) 6.9 (3.6)
 Median (IQR) 6.0 (4.0–9.0)
 Range 2–17
Imprecisely documented infusions, no. (%) (total no. = 3949) 370 (9)










 GLUC 4.6%–NaCl 0.9% 114
Most frequent pairs of infusions in all coadministered infusions, no. (total no. = 1447)*
 Morphine + midazolam 232
 Furosemide + heparin Na 105
 Adrenaline + noradrenaline 96
 PN + fat emulsion 20% 95
 PN + PN 61
 Noradrenaline + milrinone 60
 Fentanyl + midazolam 58
 Morphine + GLUC 9.1%–NaCl 0.9% 44
 Morphine + Misch 4:1 10% 42
 Morphine + NaCl 0.9% 39
CVC, central venous catheter; GLUC, glucose solution; Misch, solution of glucose and sodium chloride (4:1); PN, parenteral nutrition
* Combinations are composed of 2 or more infusions; therefore, the total no. of listed infusions exceeds the total of incompatible combinations.
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surrogates for the severity of the patient’s condition 
and are thereby associated with the number of infu-
sions and lumina.
This study features several strengths. Although many 
other studies exclude blood products and parenteral 
nutrition, we considered these administrations as well. 
In contrast to assessments that simply rely on data as 
documented in the electronic patient records, evalu-
ating the quality of documentation confirmed that our 
raw data was representative for the administration of 
continuous infusions in clinical practice.
With 10% of the infusion combinations classified as 
incompatible, the proportion of incompatible combina-
tions is apparently higher compared with other previ-
ous studies. Gikic et al11 found a rate of 3.4% in 2000 
in another Swiss PICU/NICU. Gaetani et al12 analyzed 
administration data from 2006 to 2015 and identified 
9% of incompatible intravenous infusion administrations 
in critically ill children. Other recent studies performed 
in adult patients exposed to multiple IV drugs have 
found incompatible combinations in 12% to 56%.19,20 
However, these differences can be explained using 
different references and methods. Contrary to other 
similar studies, we did not exclude any drugs or infu-
sions (i.e., we collected data of all continuous infusions, 
including electrolytes, PN, and blood products). Indeed, 
the latter two accounted for approximately 50% of all 
incompatible situations. Furthermore, we recorded 
data 24/7, albeit without considering injections and 
short infusions.
In our study infusion combinations were classified 
looking primarily at the internal compatibility charts. 
These have been developed by the pharmaceutical 
services to improve drug administration and patient 
safety. They cover combinations occurring frequently 
in clinical practice, even if no primary data on compat-
ibility are available. The internal compatibility charts 
categorizing certain combinations as incompatible (e.g., 
because of their extreme pH values, composition of 
proteins/biologicals, buffers) may be classified as “no 
data” in other references or studies, thereby increasing 
the incidence of incompatible situations. The internal 
compatibility charts allowed the identification of all in-
compatible combinations and most combinations. Most 
combinations which were not covered by these charts 
were also not listed in the other references. However, 
it is important to note that a combination without com-
patibility data may be incompatible, especially if the 
involved infusions feature critical characteristics, such 
as stabilizers, buffers, solvents, or extreme pH values. 
Care teams should be trained regarding this potential 
problem to promote combinations of infusions with 
favorable compatibility data available.
Among infusions frequently involved in incompat-
ible situations, many feature an extreme pH value. 
Although an acidic pH is common and may frequently 
be combined with similarly acidic infusions, infusions 
such as tranexamic acid or furosemide are alkaline, 
and as such more likely to lead to incompatibilities. It is 
therefore important to note that certain acidic infusions, 
like morphine or midazolam, frequently appear among 
the infusions involved in many incompatible situations. 
Yet in most cases, the incompatibility was related to 
the coadministration of these infusions with alkaline 
infusions, such as tranexamic acid or furosemide, or 
generally less stable infusions, like propofol, PN, or 
blood products. Our analysis of incompatible situations 
revealed that in many cases there would have been a 
Table 4. Combination Types of Infusions
Combinations No. (%)
With 2 infusions 1077 (74.4)
With 3 infusions 301 (20.8)
With 4 infusions 53 (3.7)
With 5 infusions 13 (0.9)
With 6 infusions 2 (0.1)
With 7 infusions 1 (0.1)
Total combinations 1447 (100)
Classification Combinations Covered by 
Internal Charts, no. (%)
Combinations From Another Reference 
Not Featuring in Internal Charts, no. (%)*
Total, no. (%)
Incompatible 146 (10) 0 146 (10)
No data 39 (3) 168 (12) 207 (15)
Compatible 1061 (73) 13 (1) 1074 (74)
Variable 15 (1) 4 (0) 19 (1)
Total combinations 1261 (87) 185 (13) 1447 (100)
* Trissel’s database and Swiss summary of product characteristics.
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 Oral administration possible 58 (55)
 Theoretical compatible lumen distribution 61 (58)
 Patients (n = 100) exposed to an incompatible situation 46 (46)
Incompatible infusion combinations (total no. = 146)
 Featuring on internal compatibility charts 146
 Thereof also specified in Trissel’s* 2
 Thereof also explicitly listed in the Swiss SPC 10
Most frequently involved infusions in incompatible combinations (total no. = 146)*
 1. Blood products† 50
 2. Midazolam 45





 8. Fat emulsion 20% 11
 9. Alprostadil 11
 10. Clonidine HCl 10
Most frequent incompatible combinations (total no. = 146)*
 1. Blood products‡ + any other infusion 50
 2. Tranexamic acid + midazolam 24
 3. PN/fat emulsion 20% + any other incompatible infusion 23
 4. Tranexamic acid + morphine 22
 5. Propofol + morphine 8
Most frequent individual combinations without data on compatibility (total no. = 1447)§
 1. Morphine + GLUC 9.1%–NaCl 0.9% 44
 2. Milrinone + GLUC 9.1%–NaCl 0.9% 16
 3. Ringeracetat with 1% GLUC + morphine 14
 4. Noradrenaline + GLUC 9.1%–NaCl 0.9% 12
 5. Furosemide + ranexamic acid 7
GLUC, glucose solution; PN, parenteral nutrition; SPC, summary of product characteristics 
* One incompatible combination featured in both references, i.e., Swiss SPC and Trissel’s.
†  Incompatible combinations may be due to a combination of multiple infusions; therefore, the total no. of listed infusions exceeds the total of 
incompatible combinations.
‡ Erythrocyte concentrate, thrombocyte concentrate, fresh frozen plasma, blood plasma, human albumin.
§ Combinations are composed of 2 or more infusions; therefore, the total no. of listed infusions exceeds the total of incompatible combinations.
theoretically compatible arrangement of infusions if 
they had been redistributed, for example, by combin-
ing certain acidic infusions in one lumen to allow more 
problematic products to be administered separately. 
Yet, these are academic considerations, which may not 
fully represent the clinical situation during which the 
incompatibility occurred. Because of their expertise, 
members of pharmaceutical services may be able to 
promote such a preferable distribution of the infusions 
among the available catheters and lumina, thereby 
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avoiding incompatibilities or at least minimizing their 
likelihood if no specific data are available.
Our study also has some limitations: only data from 
46% of all patients admitted to the PICU/NICU were 
considered. We consider it unlikely that the exclusion of 
patients who refused consent to using their data likely 
biased our results. And patients who were not included 
because they had no intravenous coadministrations of 
continuous infusions were a priori not part of the at-
risk population. However, we could not consider the IV 
injections and infusions lasting <15 minutes, and those 
may likely have further increased the frequency of in-
compatible combinations. Our categorization regarding 
the compatibility was limited to 3 chosen references, 
with the principal reference being internally developed 
compatibility charts, which limits the generalizability of 
our results. However, the internal compatibility charts 
are based on physicochemical properties to promote a 
safe yet pragmatic coadministration of infusions. Finally, 
we did not perform a systematic analysis regarding 
the clinical relevance of the detected incompatible 
coadministrations because this was beyond the scope 
of the present study.
Based on our findings, we suggest the following 
specific measures to further reduce the rate of incom-
patibilities: (1) discussions and subsequent training with 
PICU/NICU care teams regarding incompatibilities and 
the use of the internal compatibility charts, (2) a list spe-
cifically designed for the care teams that highlights the 
most critical infusions (which whenever possible should 
be administered alone), and finally (3) the addition of 
a function in the patient data management system 
software which automatically checks the compatibility 
of any documented infusion, issuing an automated 
warning in case of incompatible combinations.
Future research could aim to evaluate these mea-
sures—similarly to the introduction of in-line filters, they 
may serve to reduce the number of severe complica-
tions, length of stay, and thereby costs on our PICU/
NICU.6
Conclusion
The results of this study reveal that incompatible 
coadministrations of continuous infusions occur daily 
on the assessed PICU/NICU. The most frequently in-
volved infusions were blood products, PN, emulsions, 
and infusions with extreme pH values. Sometimes 
coadministration of formally incompatible infusions is 
unavoidable because of the limited number of lumina. 
However, we found that for most incompatible situa-
tions an alternative distribution of the infusions among 
the existing lumens has been feasible.
Given that the internal compatibility charts covered 
all incompatible combinations as well as most ap-
plied combinations, they currently do not require any 
fundamental modifications. The main action required 
currently is likely educating care teams about incompat-
ibilities. The pharmaceutical services can and should 
help improve the patients’ safety by promoting an 
optimal distribution of continuous infusions.
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Figure 2. Incompatible situation according to the number of infusions and the number of lumina.
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